Document Detail


Immunoactive effects of cannabinoids: considerations for the therapeutic use of cannabinoid receptor agonists and antagonists.
MedLine Citation:
PMID:  20219697     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The active constituents of Cannabis sativa have been used for centuries as recreational drugs and medicinal agents. Today, marijuana is the most prevalent drug of abuse in the United States and, conversely, therapeutic use of marijuana constituents are gaining mainstream clinical and political acceptance. Given the documented contributions of endocannabinoid signaling to a range of physiological systems, including cognitive function, and the control of eating behaviors, it is unsurprising that cannabinoid receptor agonists and antagonists are showing significant clinical potential. In addition to the neuroactive effects of cannabinoids, an emerging body of data suggests that both endogenous and exogenous cannabinoids are potently immunoactive. The central premise of this review article is that the immunological effects of cannabinoids should be considered in the context of each prescribing decision. We present evidence that the immunological effects of cannabinoid receptor agonists and antagonists are highly relevant to the spectrum of disorders for which cannabinoid therapeutics are currently offered.
Authors:
William E Greineisen; Helen Turner
Related Documents :
11384777 - Antibodies raised against the extracellular tail of the cckb/gastrin receptor inhibit g...
23481697 - Two newly identified exons in human grm1 express a novel splice variant of metabotropic...
24814197 - Discovery of novel 2-((pyridin-3-yloxy)methyl)piperazines as α7 nicotinic acetylcholine...
24312457 - Homotypic and heterotypic adhesion induced by odorant receptors and the β2-adrenergic r...
12386287 - Angiotensin ii and tubular development.
21742547 - Acetate recognition by 2,6-bis(2-benzimidazolyl)pyridine.
Publication Detail:
Type:  Journal Article; Review     Date:  2010-02-25
Journal Detail:
Title:  International immunopharmacology     Volume:  10     ISSN:  1878-1705     ISO Abbreviation:  Int. Immunopharmacol.     Publication Date:  2010 May 
Date Detail:
Created Date:  2010-04-13     Completed Date:  2010-09-08     Revised Date:  2013-12-22    
Medline Journal Info:
Nlm Unique ID:  100965259     Medline TA:  Int Immunopharmacol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  547-55     Citation Subset:  IM    
Copyright Information:
Copyright 2010 Elsevier B.V. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Anti-Inflammatory Agents* / pharmacology,  therapeutic use
Autoimmune Diseases / drug therapy*,  immunology
Cannabinoids* / pharmacology,  therapeutic use
Cytokines / secretion
Drug Administration Routes
Histamine Release / drug effects
Humans
Hypersensitivity / drug therapy*,  immunology
Immunity, Cellular / drug effects
Immunosuppression
Inflammatory Bowel Diseases / drug therapy*
Phagocytosis / drug effects
Pulmonary Disease, Chronic Obstructive / drug therapy*
Receptor, Cannabinoid, CB1 / agonists*
Receptor, Cannabinoid, CB2 / antagonists & inhibitors*
Grant Support
ID/Acronym/Agency:
P20 MD006084/MD/NIMHD NIH HHS; P20 RR016467/RR/NCRR NIH HHS
Chemical
Reg. No./Substance:
0/Anti-Inflammatory Agents; 0/Cannabinoids; 0/Cytokines; 0/Receptor, Cannabinoid, CB1; 0/Receptor, Cannabinoid, CB2
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Natural regulatory T cells mediate the development of cerebral malaria by modifying the pro-inflamma...
Next Document:  Partitioning of exhaled NO in ventilated patients undergoing cardiac surgery.